A Phase 2 interventional study of EVO101 in Atopic Dermatitis Eczema, sponsored by Evommune, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-05.
Sponsored by Evommune, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.
Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 247th largest by enrollment of the 544 interventional ones that give a count, is one of 45 that started in 2022, is one of 202 in phase 2, and was the 480th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 12–120
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Triveni Bio · Sites in United States, Canada, Ukraine
Ages 18–75
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
639 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 97 · Phase 2 221 · Phase 3 107 · Phase 4 70
First in 1996; this study’s year is marked. 45 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 96 across the 544 interventional studies, 155 across the 94 observational. Of the 491 that completed or were terminated, 265 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
429 of 639 have an industry lead sponsor. The 10 most frequent:
Evommune, Inc. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Evommune, Inc. has 3 studies filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
42 of the studies in Dermatitis, Atopic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06389136Phase 3AbbVieA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab | 2026-11 |
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
Add all 42 to your calendar (.ics) → With an account.
Among the 639 studies in Dermatitis, Atopic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
This is a Phase 2a safety and efficacy study of EVO101 Topical Cream, 0.1%, applied twice daily for 8 weeks in adults with mild-to moderate atopic dermatitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Active Treatment, BID, 8 weeks
Drug: EVO101
Vehicle Treatment, BID, 8 weeks
Drug: EVO101
Topical Cream
Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8
EASI assesses the extent and severity of atopic dermatitis. EASI is a composite index with scores ranging from 0 to 72. Higher values indicate more severe or extensive disease.
Time frame: 8 weeks
Investigator Global Assessment (IGA) Response (Number of Participants With >= 2 Points Change From Baseline to Week 8)
The IGA assesses the overall appearance and severity of atopic dermatitis using a 5-point scale \[0 (clear) to 4 (severe)\]. The outcome measures is reported as the number of participants achieving a reduction of 2 or greater on the IGA from baseline to Week 8.
Time frame: 8 weeks
Percent Body Surface Area (BSA) Affected by Atopic Dermatitis Over Time, Change From Baseline to Week 8
BSA estimates the extent of atopic dermatitis involvement and is expressed as a percentage of total body surface area. The outcome measure describes the mean change from baseline in percent of the body surface area affected by AD.
Time frame: 8 weeks
Pruritus-NRS, Change From Baseline to Week 8
The pruritus-NRS is an 11-point scale used by subjects to rate their worst itch severity over the past 24 hours with 0 indicating "no itch" and 10 indicating "worst itch imaginable".
Time frame: 8 weeks
| Milestone | EVO101 Cream | Vehicle Cream |
|---|---|---|
| Started | 60 | 59 |
| Completed | 57 | 51 |
| Not completed | 3 | 8 |
| Withdrew: Lost to follow-up | 3 | 1 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Pregnancy | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 3 |
EASI assesses the extent and severity of atopic dermatitis. EASI is a composite index with scores ranging from 0 to 72. Higher values indicate more severe or extensive disease.
| Percent change from baseline | EVO101 Cream | Vehicle Cream |
|---|---|---|
| Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 | -43.5 ± 60.85 | -62.0 ± 38.78 |
The IGA assesses the overall appearance and severity of atopic dermatitis using a 5-point scale \[0 (clear) to 4 (severe)\]. The outcome measures is reported as the number of participants achieving a reduction of 2 or greater on the IGA from baseline to Week 8.
| Participants | EVO101 Cream | Vehicle Cream |
|---|---|---|
| Yes | 20 | 23 |
| No | 37 | 28 |
BSA estimates the extent of atopic dermatitis involvement and is expressed as a percentage of total body surface area. The outcome measure describes the mean change from baseline in percent of the body surface area affected by AD.
| percentage of total body surface area | EVO101 Cream | Vehicle Cream |
|---|---|---|
| Percent Body Surface Area (BSA) Affected by Atopic Dermatitis Over Time, Change From Baseline to Week 8 | -2.1 ± 6.45 | -3.5 ± 2.99 |
The pruritus-NRS is an 11-point scale used by subjects to rate their worst itch severity over the past 24 hours with 0 indicating "no itch" and 10 indicating "worst itch imaginable".
| Change in units on a scale | EVO101 Cream | Vehicle Cream |
|---|---|---|
| Pruritus-NRS, Change From Baseline to Week 8 | -2.5 ± 2.16 | -3.5 ± 2.55 |
Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EVO101 Cream | 0/60 (0%) | 0/60 (0%) | 19/60 (31.7%) |
| Vehicle Cream | 0/58 (0%) | 0/58 (0%) | 30/58 (51.7%) |
| Event | EVO101 Cream | Vehicle Cream |
|---|---|---|
| Application site pruritusSkin and subcutaneous tissue disorders | 8/60 | 12/58 |
| Application site oedemaSkin and subcutaneous tissue disorders | 3/60 | 11/58 |
| Application site erythemaSkin and subcutaneous tissue disorders | 4/60 | 10/58 |
| Application site drynessSurgical and medical procedures | 2/60 | 8/58 |
| Application site painSkin and subcutaneous tissue disorders | 6/60 | 7/58 |
| Application site exfoliationSkin and subcutaneous tissue disorders | 3/60 | 7/58 |
| Age, Categorical(Participants) | EVO101 Cream | Vehicle Cream | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 51 | 55 | 106 |
| >=65 years | 9 | 4 | 13 |
| Sex: Female, Male(Participants) | EVO101 Cream | Vehicle Cream | Total |
|---|---|---|---|
| Female | 37 | 37 | 74 |
| Male | 23 | 22 | 45 |
| Ethnicity (NIH/OMB)(Participants) | EVO101 Cream | Vehicle Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 20 | 24 | 44 |
| Not Hispanic or Latino | 39 | 32 | 71 |
| Unknown or Not Reported | 1 | 3 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data that underlie the results published, after deidentification (text, tables, figures, and appendices)
Supporting information: Study protocol
Time frame: Following publication
Access criteria: to be determined
Ran from Sep 2022 to primary completion in Jul 2023, 10 months.
Results were first posted in Mar 2025, 1 year 7 months after primary completion.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 10 months is below that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Evommune, Inc.